文献速递肾移植

无供者特异性HLA抗体时移植肾小球病的危险因素、病理特征与移植物结局

Risk factors, histopathological features, and graft outcome of transplant glomerulopathy in the absence of donor-specific HLA antibodies.
PubMed 文献 · Kidney Int · 2021-03-03

该回顾性队列纳入2004-2013年954例肾移植受者(3744次活检),发现10.3%发生移植肾小球病,平均术后3.2年;其中76.5%无HLA-DSA。仅HLA-DSA是危险因素,无HLA-DSA者炎症和C4d沉积更少,移植物失败风险更低。

要点

  • 移植肾小球病可发生在无HLA-DSA者中,占76.5%,独立于HLA分子错配。
  • 无HLA-DSA的移植肾小球病炎症和C4d沉积更少,移植物存活更好。
  • HLA-DSA阳性移植肾小球病移植物失败风险显著更高(HR 3.84)。

核心结论

  • 移植肾小球病常发生在无HLA-DSA的情况下,独立于HLA分子错配,且表型不同、移植物存活更好。

研究设计与样本

  • 回顾性研究纳入2004-2013年954例肾移植患者(3744次活检),对供受者进行高分辨率HLA基因分型。

主要发现

  • 10.3%发生移植肾小球病,平均术后3.2年;其中23.5%有持续性或新发HLA-DSA,76.5%无HLA-DSA。
  • 仅HLA-DSA是移植肾小球病的危险因素,而HLA-DSA阴性活检的间质炎症、肾小球炎和管周毛细血管C4d沉积均少于阳性活检。
  • HLA-DSA阳性移植肾小球病的移植物失败风险显著高于阴性(HR 3.84;95%CI 1.94-7.59)。
  • 术后3年landmark分析显示,无HLA-DSA的移植肾小球病患者移植物失败风险仍显著增加(HR 2.62;95%CI 1.46-4.72)。

临床怎么用

  • 对无HLA-DSA的移植肾小球病患者,应认识到其仍存在移植物失败风险,需密切监测。

局限性

  • 回顾性设计;PIRCHE-II评分和eplet错配未显示关联;未报告其他潜在危险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transplant glomerulopathy is established as a hallmark of chronic antibody-mediated rejection in kidney transplant patients with donor-specific HLA antibodies (HLA-DSA). The clinical importance of transplant glomerulopathy in the absence of HLA-DSA is not well established. To help define this, 954 patients (encompassing 3744 biopsies) who underwent kidney transplantation 2004-2013 were studied with retrospective high-resolution HLA genotyping of both donors and recipients. The risk factors, histopathological appearance and prognosis of cases with transplant glomerulopathy in the absence of HLA-DSA were compared to those cases with HLA-DSA, and the impact of the PIRCHE-II score and eplet mismatches on development of transplant glomerulopathy evaluated. In this cohort, 10.3% developed transplant glomerulopathy, on average 3.2 years post-transplant. At the time of glomerulopathy, 23.5% had persistent pre-transplant or de novo HLA-DSA, while 76.5% were HLA-DSA negative. Only HLA-DSA was identified as a risk factor for glomerulopathy development as eplet mismatches and the PIRCHE-II score did not associate. HLA-DSA negative biopsies with glomerulopathy had less interstitial inflammation, less glomerulitis, and less C4d deposition in the peritubular capillaries compared to the HLA-DSA positive biopsies with glomerulopathy. While graft function was comparable between the two groups, HLA-DSA positive glomerulopathy was associated with a significantly higher risk of graft failure compared to HLA-DSA negative glomerulopathy (Hazard Ratio 3.84; 95% confidence interval 1.94-7.59). Landmark analysis three-years post-transplant showed that HLA-DSA negative patients with glomerulopathy still had a significant increased risk of graft failure compared to patients negative for glomerulopathy (2.62; 1.46-4.72). Thus, transplant glomerulopathy often occurs in the absence of HLA-DSA, independent of HLA molecular mismatches, and represents a different phenotype with less concomitant inflammation and better graft survival compared to that developed in the presence of HLA-DSA.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Senev A, Van Loon E, Lerut E, et al. Risk factors, histopathological features, and graft outcome of transplant glomerulopathy in the absence of donor-specific HLA antibodies. Kidney Int. 2021. PMID: 33675843. doi:10.1016/j.kint.2021.01.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。